IntraMed - Artículos - Eritrocitosis
Diagnóstico y tratamiento | 23 DIC 13


Actualización de los métodos diagnósticos y el manejo de los pacientes con eritrocitosis.
Autor: Dres. Clodagh Keohane, Mary Frances McMullin, Claire Harrison BMJ 2013;347:f6667
INDICE:  1.  | 2. Referencias

1 Mehta J, Wang H, Iqbal SU, Mesa R. Epidemiology of myeloproliferative neoplasms in the United States. Leuk Lymphoma 2013; published online 29 Jul.
2 McMullin MF, Bareford D, Campbell P, Green AR, Harrison C, Hunt B, et al. Guidelines for the diagnosis, investigation and management of polycythaemia/erythrocytosis. Br J Haematol 2005;130:174-95.
3 Burge PS, Johnson WS, Prankerd TA. Morbidity and mortality in pseudopolycythaemia. Lancet 1975;1:1266-9.
4 Weinreb NJ, Shih CF. Spurious polycythemia. Semin Hematol 1975;12:397-407. 5 Lowe GD. Rheological influences on thrombosis. Baillieres Best Pract Res Clin Haematol 1999;12:435-49.
6 Messinezy M, Pearson TC. A retrospective study of apparent and relative polycythaemia: associated factors and early outcome. Clin Lab Haematol 1990;12:121-9.
7 Gagnon DR, Zhang TJ, Brand FN, Kannel WB. Hematocrit and the risk of cardiovascular disease—the Framingham study: a 34-year follow-up. Am Heart J 1994;127:674-82.
8 James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.
9 Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-51.
10 Messinezy M, Macdonald LM, Nunan TO, Westwood NB, Chinn S, Pearson TC. Spleen sizing by ultrasound in polycythaemia and thrombocythaemia: comparison with SPECT. Br J Haematol 1997;98:103-7.
11 Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, et al. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-61.
12 Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-64.
13 Barbui T, Carobbio A, Rambaldi A, Finazzi G. Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor? Blood 2009;114:759-63.
14 Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR.
Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986;23:132-43.
15 Marchioli R, Finazzi G, Specchia G, Cacciola R, Cavazzina R, Cilloni D, et al. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med 2013;368:22-33.
16 Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.
17 Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-32.
18 Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83.
19 Kiladjian JJ, Chevret S, Dosquet C, Chomienne C, Rain JD. Treatment of polycythemia vera with hydroxyurea and pipobroman: final results of a randomized trial initiated in 1980. J Clin Oncol 2011;29:3907-13.
20 Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.
21 Criner GJ. Effects of long-term oxygen therapy on mortality and morbidity. Respir Care 2000;45:105-18.
22 Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2005;4:CD001744.
23 Crockett AJ, Cranston JM, Moss JR, Alpers JH. Survival on long-term oxygen therapy in chronic airflow limitation: from evidence to outcomes in the routine clinical setting. Int Med J 2001;31:448-54.
24 Stuart-Harris C, Bishop JM, Clark TJH, Dornhorst AC, Cotes JE, Flenley DC, et al. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic bronchitis and emphysema: report of the Medical Research Council Working Party. Lancet 1981;317:681-6.
25 Kvale PA, Cugell DW, Anthonisen NR, Timms RM, Petty TL Boylen TC, et al. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive lung disease: a clinical trial. Ann Intern Med 1980;93:391-8.
26 Wade JP, Pearson TC, Russell RW, Wetherley-Mein G. Cerebral blood flow and blood viscosity in patients with polycythaemia secondary to hypoxic lung disease. BMJ 1981;283:689-92.
27 Wedzicha JA, Rudd RM, Apps MC, Cotter FE, Newland AC, Empey DW. Erythrapheresis in patients with polycythaemia secondary to hypoxic lung disease. BMJ 1983;286:511-4.
28 Weisse AB, Moschos CB, Frank MJ, Levinson GE, Cannilla JE, Regan TJ. Hemodynamic effects of staged hematocrit reduction in patients with stable cor pulmonale and severely elevated hematocrit levels. Am J Med 1975;58:92-8.
29 Harrison BD, Stokes TC. Secondary polycythaemia: its causes, effects and treatment. Br J Dis Chest 1982;76:313-40.
30 Perloff JK, Rosove MH, Child JS, Wright GB. Adults with cyanotic congenital heart disease: hematologic management. Ann Intern Med 1988;109:406-13.
31 Diller GP, Gatzoulis MA. Pulmonary vascular disease in adults with congenital heart disease. Circulation 2007;115:1039-50.
32 Wickre CG, Norman DJ, Bennison A, Barry JM, Bennett WM. Postrenal transplant erythrocytosis: a review of 53 patients. Kidney Int 1983;23:731-7.
33 Yildiz A, Cine N, Akkaya V, Sahin S, Ismailoglu V, Turk S, et al. Comparison of the effects of enalapril and losartan on posttransplantation erythrocytosis in renal transplant recipients: prospective randomized study. Transplantation 2001;72:542-4.
34 Julian BA, Brantley RR, Barker CV, Stopka T, Gaston RS, Curtis JJ, et al. Losartan, an angiotensin II type 1 receptor antagonist, lowers hematocrit in posttransplant erythrocytosis. J Am Soc Nephrol 1998;9:1104-8.
35 Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990;323:86-90.


Usted debe estar registrado para expresar su opinión. Si ya es usuario de IntraMed o desea registrase como nuevo usuario, ingrese aquí
Dr. Oscar Enrico Acosta Vargas   Hace 21 días
Muchas gracas por la actualización, en temas como este que se ve bastante en la consulta externa. Un abrazo a todos los miembros de IntraMed.
Dr. Eusebio Paytan Cuba   Hace 1 año
Excelente articulo gracias a todos los integrantes de IntraMed que nos actualizan en el dia a dia en busca del conocimiento mas elevado.
Términos y condiciones de uso | Todos los derechos reservados | Copyright 1997-2017